This may be an area of substantial future research directions due to the rising popularity of GLP-1 medications
The Editor should be informed at the time of the Submission of any article that has been submitted to or published in another publication
Recent studies have shown promising results for AOMs in addressing both obesity and OSA, highlighting the potential of AOMs to leading to substantial cost savings in healthcare systems
Most clinical guidance recommends: At 3 months: A1c recheck (HbA1c reflects the prior 3-month average, making this the earliest timepoint for meaningful assessment of glycemic response), metabolic panel if any GI side effects were significant At 6 months: Full panel repeat A1c, CMP, lipids, CBC to document treatment response comprehensively Annually: Full panel plus thyroid function, B12, and any additional markers relevant to your individual health picture If you experience severe or persistent gastrointestinal side effects, signs of dehydration, unusual fatigue, or any concerning symptoms, kidney function should be rechecked without waiting for a scheduled interval
